Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the ...
Purdue Pharma L.P. ("Purdue") has entered into an agreement to have its pipeline medication tinostamustine included in the Phase 2/3 GBM AGILE (Glioblastoma Adaptive Global Innovative Learning ...
The Australian Patent Office has issued a Decision to Grant for Oryzon’s patent application AU2020249493, titled ...
Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne ...
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...
The HDAC inhibitor pipeline remains active, with several next-generation agents advancing in clinical trials. Abexinostat (Xynomic Pharmaceuticals) is in Phase III development for renal cell carcinoma ...
The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic colorectal cancer to begin. The U.S. Food and Drug Administration (FDA) ...
China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday, Chinese ...
The evolution of biomedical science can be appreciated through studies of hemoglobin, the oxygen-carrying protein in red cells. Before molecular cloning, the geneticist Arno Motulsky noted, “Many ...
Epigenetic modifications significantly influence gene expression and play crucial roles in various biological processes, including carcinogenesis. This study investigates the effects of novel ...
Therapeutics for peripheral neuropathies, such as Charcot-Marie-Tooth (CMT) disease, are still quite limited and focus on managing symptoms. Augustine Therapeutics NV has presented an orally available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback